title: Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study.
abstract: OBJECTIVE
  To determine the survival and clinical effectiveness of leflunomide (LEF) compared with methotrexate (MTX) and sulfasalazine (SSZ) for RA in an observational study.
  
  
  METHODS
  An observational database of 1088 patients and 5141 patient years of DMARD treatment (2680 courses) from two academic hospitals was filtered for treatment with LEF, MTX, and SSZ. LEF treatment groups were matched for patients' age, baseline ESR, number of previous DMARDs, and hospital cohort with MTX and SSZ treatment groups. For these treatments, Kaplan-Meier analyses of time until the drug was discontinued (drug "survival"), and the effectiveness and safety of continuation of treatment, were performed. The change in disease activity markers (CRP, ESR) was compared between the groups.
  
  
  RESULTS
  The median dose during the study increased from 10 to 15 mg MTX/week and from 1.5 to 2.0 g SSZ/day. Matched survival analysis showed better retention rates for MTX (mean (SEM) survival 28 (1) months) than for LEF (20 (1) months; p=0.001), whereas retention rates of SSZ (23 (1) months) were similar to those of LEF (p=NS). Treatments were stopped earlier because of adverse events (AEs, 3 months) than because of ineffectiveness (IE, 10 months; p<0.001). LEF and MTX were less likely to be stopped because of AEs than SSZ. LEF courses were stopped earlier for AEs (p<0.001) than MTX.
  
  
  CONCLUSIONS
  Current dosing strategies should be re-evaluated, and coping strategies for common AEs should be investigated. This will be necessary to achieve better drug retention of LEF. At present, MTX continues to be the most effective drug in clinical practice.
authors.affiliation: Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Austria. daniel.aletaha@akh-wien.ac.at
authors.forename: D
authors.initials: D
authors.lastname: Aletaha
authors.forename: T
authors.initials: T
authors.lastname: Stamm
authors.forename: T
authors.initials: T
authors.lastname: Kapral
authors.forename: G
authors.initials: G
authors.lastname: Eberl
authors.forename: J
authors.initials: J
authors.lastname: Grisar
authors.forename: K P
authors.initials: KP
authors.lastname: Machold
authors.forename: J S
authors.initials: JS
authors.lastname: Smolen
mesh_terms: D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000032:analysis; D016009:Chi-Square Distribution; D016208:Databases, Factual; D005260:Female; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use*; D000077339:Leflunomide; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D018709:Statistics, Nonparametric; D012460:Sulfasalazine / Q000627:therapeutic use; D013997:Time Factors; D017211:Treatment Failure
chemical_list: D018501:Antirheumatic Agents; D007555:Isoxazoles; D012460:Sulfasalazine; D002097:C-Reactive Protein; D000077339:Leflunomide; D008727:Methotrexate